Core Insights - LifeVantage Corporation has appointed Mike Edwards as Chief Technology Officer, bringing over 25 years of experience in technology leadership and enterprise transformation [1][2]. Company Overview - LifeVantage Corporation, listed on Nasdaq as LFVN, specializes in health and wellness products that activate optimal health processes at the cellular level [1][5]. - The company is a pioneer in nutrigenomics, focusing on how nutrition and naturally occurring compounds can unlock genetic health potential [5]. Leadership and Strategy - Mike Edwards is recognized as a strategic leader with a strong track record in translating technological innovation into measurable business impact, which is expected to accelerate LifeVantage's digital transformation [2]. - His expertise includes eCommerce, AI, CRM systems, and mobile technology, which will be critical for expanding the company's global footprint and enhancing technology solutions for independent consultants and customers [2][4]. Technology and Innovation - Edwards has previously led comprehensive transformation initiatives in eCommerce platforms, AI implementation, and customer experience enhancement, modernizing legacy systems and scaling global eCommerce infrastructure [3][2]. - The focus will be on leveraging cutting-edge technology to streamline operations and create seamless experiences for consultants and customers [4].

SALT LAKE CITY, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the 28th Annual ICR Conference to be held January 12-14, 2026 in Orlando, FL. Mr. Fife and Mr. Aure will present at approximately 1:00 p.m. Eastern Time on Monday, Janua ...

Core Insights - LifeVantage Corporation, a leader in health and wellness, focuses on activating optimal health processes at the cellular level [1] - The company will participate in the Water Tower Fireside Chat Series on December 11, 2025, featuring CEO Steve Fife and CFO Carl Aure [1][2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, which studies how nutrition and natural compounds can unlock genetic health [3] - The company's product line includes Protandim® family, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and P84, among others [3] - LifeVantage also offers activation-supporting nutrients like Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drinks and TrueScience® skin and hair care products [3] - Founded in 2003 and headquartered in Lehi, Utah, LifeVantage operates through independent consultants who sell products and offer business opportunities [3]

Core Insights - LifeVantage Corporation reported a revenue of $47.6 million for the first quarter of fiscal 2026, reflecting a 0.7% increase year-over-year [5][10] - The company is focusing on the strategic acquisition of LoveBiome, which positions it as a leader in the natural GLP-1 activation and microbiome health markets [4] - The company expects revenue growth to accelerate in the second half of the fiscal year due to seasonality and the impact of the LoveBiome acquisition [15] Financial Performance - Revenue for the first quarter of fiscal 2026 was $47.6 million, a 0.7% increase from the same period in fiscal 2025 [5][10] - Gross profit was $37.8 million, representing 79.5% of revenue, slightly down from 79.9% in the previous year [6] - Net income for the first quarter was $2.2 million, or $0.17 per diluted share, compared to $1.8 million, or $0.14 per diluted share in the prior year [10][11] Expense Analysis - Commissions and incentives expense increased to $20.7 million, or 43.5% of revenue, up from 43.0% in the previous year [7] - Selling, general and administrative (SG&A) expenses were $14.9 million, or 31.2% of revenue, slightly down from 31.4% in the prior year [8] - Adjusted EBITDA for the first quarter was $3.9 million, compared to $4.4 million in the same period last year [11] Balance Sheet & Liquidity - The company used $2.3 million of cash from operations during the first three months of fiscal 2026, compared to $0.6 million in the same period of fiscal 2025 [12] - Cash and cash equivalents at September 30, 2025, were $13.1 million, down from $20.2 million at June 30, 2025 [12] Shareholder Returns - LifeVantage repurchased 44,000 common shares for approximately $0.6 million during the first quarter [13] - A cash dividend of $0.045 per common share was declared, to be paid on December 15, 2025 [14] Guidance - The company reiterated its revenue guidance for fiscal 2026 in the range of $225 million to $240 million, with adjusted EBITDA expected between $23 million and $26 million [15]

Core Viewpoint - LifeVantage Corporation will release its financial results for the first quarter ended September 30, 2025, on November 4, 2025, after market close, followed by a conference call for investors [1] Financial Results Announcement - The financial results will be announced after the stock market closes on November 4, 2025 [1] - A conference call for investors is scheduled for 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day [1] Participation Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and can be accessed until November 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation has successfully completed the acquisition of LoveBiome, enhancing its position in the direct sales and gut health market [1][2] - The acquisition allows LifeVantage to expand its product portfolio into the growing microbiome health sector and strengthen its market presence in the US, Taiwan, and Europe [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] - LifeVantage operates through independent consultants who sell products and provide business opportunities to aspiring entrepreneurs [3]

Group 1 - LifeVantage Corporation will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with CEO Steve Fife and CFO Carl Aure presenting [1][2] - The presentation is scheduled for approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's Investor Relations website [2] - LifeVantage specializes in nutrigenomics, offering products that activate health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] Group 2 - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, focusing on health and wellness products that work with individual biology [3] - The company also provides a business opportunity for independent consultants to sell its products and promote entrepreneurship [3]

Core Insights - LifeVantage Corporation reported a strong financial performance for the fourth quarter and full fiscal year 2025, with a revenue growth of approximately 13% to $55.1 million in Q4 and 14.2% to $228.5 million for the full year [6][9][14] - The international business showed growth for the first time in nearly three years, particularly in the Asia/Pacific and Europe regions, which increased by approximately 8% [6][9] - The company has a strong balance sheet with $20.2 million in cash and no debt, positioning it well for future growth [22] Fourth Quarter Fiscal 2025 Summary - Revenue for Q4 was $55.1 million, a 12.6% increase year-over-year, with a 14.1% increase in the Americas and a 7.6% increase in Asia/Pacific & Europe [7][9] - Gross profit was $44.0 million, representing 79.9% of revenue, compared to 79.5% in Q4 fiscal 2024 [8] - Net income for Q4 was $2.0 million, or $0.15 per diluted share, up from $1.3 million, or $0.10 per diluted share in the prior year [12][9] Fiscal Year 2025 Summary - Total revenue for fiscal 2025 was $228.5 million, a 14.2% increase from $200.2 million in fiscal 2024 [14] - Gross profit for the year was $183.7 million, or 80.4% of revenue, compared to 79.3% in fiscal 2024 [15] - Net income for the year was $9.8 million, or $0.75 per diluted share, compared to $2.9 million, or $0.23 per diluted share in fiscal 2024 [19] Share Repurchase and Dividend - The company repurchased 0.3 million shares for $3.1 million during fiscal 2025, with approximately $17.3 million remaining under the current repurchase program [21] - A cash dividend of $0.045 per common share was declared, to be paid on September 16, 2025 [23] Fiscal Year 2026 Guidance - LifeVantage expects revenue in the range of $225 million to $240 million for fiscal 2026, with adjusted EBITDA of $23 million to $26 million [24]

Core Insights - LifeVantage Corporation has announced a definitive agreement to acquire LoveBiome, a direct sales company focused on microbiome health solutions, enhancing its position in the gut health market [1][3] - The acquisition aligns with LifeVantage's mission to activate optimal health processes and expand its product offerings in the growing gut health sector [1][5] - The global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a robust CAGR of 8.4% [5] Company Strategy - The acquisition of LoveBiome is seen as a strategic move to enhance LifeVantage's Activation differentiation and broaden its community reach [1][5] - LifeVantage aims to leverage LoveBiome's expertise in microbiome science to complement its existing product portfolio, including the Protandim® family and MindBody GLP-1 System™ [1][5] - The integration of LoveBiome's innovative P84 product is expected to strengthen LifeVantage's offerings in gut health, which is increasingly recognized for its impact on overall wellness [1][5] Transaction Details - LifeVantage will acquire LoveBiome's critical operating assets and retain key personnel, including founder Kelly Olsen, to ensure operational continuity [3] - The acquisition is expected to close by mid-October, pending customary closing conditions and regulatory approvals [3] - The transaction is anticipated to enhance revenue growth and be accretive to Adjusted EPS and Adjusted EBITDA in the first year, with additional synergy opportunities [5]

Core Insights - LifeVantage Corporation will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York [1] - The company's President and CEO, Steve Fife, along with CFO Carl Aure, will present to investors on September 10, 2025, at approximately 1:00 p.m. Eastern Time [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [3] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, with a business model that includes independent consultants selling products and sharing business opportunities [3]